CN114213487B - 一种阿扎胞苷的制备方法 - Google Patents
一种阿扎胞苷的制备方法 Download PDFInfo
- Publication number
- CN114213487B CN114213487B CN202111640139.9A CN202111640139A CN114213487B CN 114213487 B CN114213487 B CN 114213487B CN 202111640139 A CN202111640139 A CN 202111640139A CN 114213487 B CN114213487 B CN 114213487B
- Authority
- CN
- China
- Prior art keywords
- stirring
- speed
- temperature
- solution
- azacitidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 title claims abstract description 46
- 229960002756 azacitidine Drugs 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title description 6
- 238000003756 stirring Methods 0.000 claims abstract description 110
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 104
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 78
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000001035 drying Methods 0.000 claims abstract description 39
- 239000002904 solvent Substances 0.000 claims abstract description 36
- 238000001816 cooling Methods 0.000 claims abstract description 29
- 238000010438 heat treatment Methods 0.000 claims abstract description 28
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 20
- 239000002244 precipitate Substances 0.000 claims abstract description 18
- 238000001914 filtration Methods 0.000 claims abstract description 17
- 238000001704 evaporation Methods 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 18
- 238000004090 dissolution Methods 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 16
- 238000007670 refining Methods 0.000 claims description 13
- 239000011521 glass Substances 0.000 claims description 12
- 239000012043 crude product Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000012264 purified product Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000005086 pumping Methods 0.000 claims description 2
- 238000011179 visual inspection Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 46
- 239000013078 crystal Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 20
- 230000003287 optical effect Effects 0.000 description 17
- 238000002425 crystallisation Methods 0.000 description 16
- 230000008025 crystallization Effects 0.000 description 16
- 239000012535 impurity Substances 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical compound NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 description 3
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 3
- 208000009527 Refractory anemia Diseases 0.000 description 3
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 2
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 238000006136 alcoholysis reaction Methods 0.000 description 2
- 238000005915 ammonolysis reaction Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- FKCRAVPPBFWEJD-XVFCMESISA-N orotidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O FKCRAVPPBFWEJD-XVFCMESISA-N 0.000 description 1
- FKCRAVPPBFWEJD-UHFFFAOYSA-N orotidine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1C(O)=O FKCRAVPPBFWEJD-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111640139.9A CN114213487B (zh) | 2021-12-29 | 2021-12-29 | 一种阿扎胞苷的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111640139.9A CN114213487B (zh) | 2021-12-29 | 2021-12-29 | 一种阿扎胞苷的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114213487A CN114213487A (zh) | 2022-03-22 |
CN114213487B true CN114213487B (zh) | 2023-12-26 |
Family
ID=80706771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111640139.9A Active CN114213487B (zh) | 2021-12-29 | 2021-12-29 | 一种阿扎胞苷的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114213487B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102850418A (zh) * | 2011-06-30 | 2013-01-02 | 杭州容立医药科技有限公司 | 一种制备高纯度阿扎胞苷的结晶及干燥方法 |
CN108929355A (zh) * | 2017-05-23 | 2018-12-04 | 正大天晴药业集团股份有限公司 | 一种阿扎胞苷晶型ⅰ的制备方法 |
CN109988207A (zh) * | 2017-12-29 | 2019-07-09 | 江苏豪森药业集团有限公司 | 阿扎胞苷晶型的制备方法 |
CN110128494A (zh) * | 2018-02-09 | 2019-08-16 | 鲁南制药集团股份有限公司 | 一种阿扎胞苷的精制方法 |
CN112300222A (zh) * | 2020-11-26 | 2021-02-02 | 北京益佰医药研究有限公司 | 一种高纯度低溶剂残留的阿扎胞苷精制方法 |
-
2021
- 2021-12-29 CN CN202111640139.9A patent/CN114213487B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102850418A (zh) * | 2011-06-30 | 2013-01-02 | 杭州容立医药科技有限公司 | 一种制备高纯度阿扎胞苷的结晶及干燥方法 |
CN108929355A (zh) * | 2017-05-23 | 2018-12-04 | 正大天晴药业集团股份有限公司 | 一种阿扎胞苷晶型ⅰ的制备方法 |
CN109988207A (zh) * | 2017-12-29 | 2019-07-09 | 江苏豪森药业集团有限公司 | 阿扎胞苷晶型的制备方法 |
CN110128494A (zh) * | 2018-02-09 | 2019-08-16 | 鲁南制药集团股份有限公司 | 一种阿扎胞苷的精制方法 |
CN112300222A (zh) * | 2020-11-26 | 2021-02-02 | 北京益佰医药研究有限公司 | 一种高纯度低溶剂残留的阿扎胞苷精制方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114213487A (zh) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114213487B (zh) | 一种阿扎胞苷的制备方法 | |
CN102850418B (zh) | 一种制备高纯度阿扎胞苷的结晶及干燥方法 | |
EP4215538A1 (en) | Method for purifying sucralose | |
CN110225918B (zh) | 阿扎胞苷晶型的制备方法 | |
CN116396312A (zh) | 一种枸橼酸艾沙佐米的制备方法 | |
CN110114333B (zh) | 赖氨酸乙酰水杨酸盐·甘氨酸颗粒的改进合成 | |
CN102557918A (zh) | 一种布洛芬钠化合物及其新制法 | |
CN111732547B (zh) | 一种奥拉帕利的精制方法及用途 | |
CN112661744B (zh) | 一种艾司奥美拉唑钠的纯化方法 | |
CA2376748C (en) | Diphosphate salt of a 4''-substituted-9-deoxo-9a-aza-9a-homoerythromycin derivative and its pharmaceutical composition | |
CN106432195B (zh) | 一种制备(r)-2-(2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺的方法 | |
EP4206211A1 (en) | Sucralose purification method | |
WO1997013775A1 (en) | New crystalline form of morphine-6-glucuronide | |
CN108440324B (zh) | 一种门冬氨酸鸟氨酸及其结晶方法 | |
US3219484A (en) | Process for the purification of sugars and their derivatives | |
CN107827944B (zh) | 一种阿扎胞苷单晶的制备方法 | |
CN114213276B (zh) | 一种从酶催化反应中提取纯化茶氨酸的方法 | |
CN114349772A (zh) | 一种比阿培南粗品的精制方法 | |
CN111378002A (zh) | 一种环黄芪醇新晶型a及其制备方法 | |
CN111410632A (zh) | 一种瑞戈非尼的精制方法 | |
CN116768910B (zh) | 一种利福布汀的精制方法 | |
CN114075109B (zh) | 一种氟比洛芬酯的制备方法及制备的晶型 | |
CN113683607B (zh) | 一种特力利汀中间体晶型ii及其制备方法 | |
CN102219793B (zh) | D(-)-磺苄西林钠的提纯方法 | |
CN112028838B (zh) | 一种2-乙氧基-5-氟尿嘧啶杂质的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240117 Address after: No. 58 Xiahong Road, High tech Industrial Development Zone, Anqing City, Anhui Province, 246002 Patentee after: Anhui Puli Pharmaceutical Co.,Ltd. Address before: 246000 No. 58, xiahong Road, high tech Industrial Development Zone, Anqing City, Anhui Province Patentee before: Anhui Puli Pharmaceutical Co.,Ltd. Patentee before: HAINAN POLY PHARM. Co.,Ltd. Patentee before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |